BSI is suggested as a prognostic tool in patients with advanced prostate cancer.
In high-risk and metastatic prostate cancer, BSI is associated with patient survival and correlates with other biomarkers of disease burden while adding independent prognostic information. 
Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17: 948-957
Poulsen M, Rasmussen J, Edenbrandt L, Høilund-Carlsen P, Gerke O, Johansen A, Lund L. Bone Scan Index predicts outcome in patients with metastatic hormone sensitive prostate cancer. BJU Int 2015 Jun 13 doi: 10.1111/bju.13160
Armstrong AJ, Kaboteh R, Carducci MA, et al. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol 2014 Nov;32(8):1308-16. doi: 10.1016/j.urolonc.2014.08.006
Kaboteh R, Damber JE, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Edenbrandt L. Bone Scan Index: A prognostic imaging biomarker for high risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Research 2013; 3: 9 doi:10.1186/2191-219X-3-9